CVS Health Misses 2026 Profit Forecast, Shares Drop
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.
/ 6 items
#CVS↓
Trump Administration Proposes Near-Flat Medicare Advantage Rates, Disappointing Insurers
Trump's CMS proposes minimal 0.09% Medicare payment increase for 2027, far below Wall Street's 4-6% expectations, while eliminating controversial billing practices.
Amazon Pharmacy Now Offers Wegovy Weight-Loss Pill with Affordable Options
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
CVS Health Boosts 2025 Outlook, Forecasts Strong 2026 Growth
CVS Health raises 2025 revenue guidance to $400B and projects adjusted earnings of $7.00-$7.20 per share for 2026, signaling turnaround momentum under CEO David Joyner.
Oscar Health Posts $137M Q3 Loss But Eyes 2026 Profitability Return
Oscar Health reports third quarter loss amid rising healthcare costs but plans return to profitability in 2026 through rate increases and market expansion in ACA insurance space.